In-Vitro Fibroblast Assay vs Clinical Outcome
The gap between a fibroblast culture result and a clinical skin outcome is the central evidential problem in cosmetic peptide marketing, because the assay removes the barrier the product must cross.
The standard cosmetic ingredient screen exposes a monolayer of human dermal fibroblasts to a test compound in culture medium for a day or several, then measures procollagen type I C-peptide, hydroxyproline, glycosaminoglycan output, metalloproteinase levels, proliferation, or migration in a scratch assay. A clinical outcome is a different object: blinded wrinkle grading, profilometry of a replica or scan, instrumental elasticity, or, rarely, histology from a biopsy.
The arithmetic is unforgiving. In culture the cell is bathed in the nominal concentration. On skin, the molecule must remain stable in the formulation, partition out of the vehicle, cross the stratum corneum against a size ceiling that excludes most peptides above about five hundred daltons, avoid retention in the corneum, survive peptidases in the viable epidermis, then diffuse into the dermis while dermal blood flow carries it away. The concentration reaching a dermal fibroblast is therefore orders of magnitude below the culture concentration. Monolayer culture also removes the tension and three-dimensional matrix that regulate fibroblast behaviour.
The asymmetry worth internalising is that this assay falsifies better than it confirms. No response at any tolerable concentration is a good reason to abandon a candidate. A strong response justifies a clinical study and nothing more; only a controlled, vehicle-compared, blinded-assessor trial supports an efficacy claim.
The specific misuse is a culture percentage printed as a skin result, usually with the exposure concentration omitted so no reader can check whether it was ever achievable. Watch also for the substitute for a real trial: an unblinded single-arm consumer panel with self-reported outcomes, presented as the clinical confirmation of the culture finding.